CROI 2020: New Data Comparing Descovy, Truvada for HIV PrEP

March 10, 2020

At the 2020 Conference on Retroviruses and Opportunistic Infections (CROI), longer-term study results on emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for HIV PrEP were presented.

New results from a clinical trial demonstrate similar efficacy between 2 pre-exposure prophylaxis (PrEP) drugs for individuals at risk for HIV infection.

The findings, which were from the 96-week DISCOVER trial, were presented at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

In the study, emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF (Descovy, Gilead) was just as effective as emtricitabine 200 mg and tenofovir disoproxil fumarate  300 mg F/TDF (Truvada). F/TAF is currently indicated to reduce the risk of sexually acquired HIV-1 infection in adults at risk of HIV infection and adolescents weighing at least 35 kg.

The phase 3 clinical study is evaluating the safety and efficacy of once-daily F/TAF for PrEP compared with F/TDF for PrEP in men and transgender women who have sex with men and are at risk for sexually acquired HIV infection. At both weeks 48 and 96, F/TAF demonstrated non-inferior efficacy to F/TDF for PrEP.

Moreover, F/TAF also showed favorable changes in key markers of renal and bone safety at week 96 compared with F/TDF for PrEP, according to the study.

The analysis showed significant differences in key markers of bone and renal safety in patients across different age groups. At week 96, there were statistically significant differences in measurements of renal safety favoring F/TAF in the overall trial population, as well as in older participants and in those with moderate renal impairment. Patients older than 50 years of age who received F/TAF showed a smaller decrease in median estimated glomerular filtration rate (eGFR) compared with those receiving F/TDF at week 96, according to the data.

Of the patients with moderate renal impairment, those who received F/TAF also had smaller changes in eGFR and markers of proximal tubular function. In this sub-group, eGFR increased by 3mL/min among those taking F/TAF and decreased by 1mL/min in those taking F/TDF.

Additionally, the findings showed changes in bone mineral density (BMD) favoring F/TAF in the overall trial population and among participants younger than 25 years of age. The data showed:

  • At week 96 in participants younger than 25 years, spine BMD increased by 1.39% in the F/TAF group and decreased by 1.2% in the F/TDF group.

  • Hip BMD increased 1.21% from baseline in the F/TAF group and decreased by 1.7% in the F/TDF group.

Those who received F/TAF had stable lipid levels through 96 weeks, the study showed. However, participants who received F/TDF showed decreases in lipid levels after 48 and 96 weeks. Fasting glucose levels were similar between the 2 groups.

“These data continue to support the role of Descovy for PrEP as an option for a range of appropriate individuals at risk for HIV infection,” said Onyema Ogbuagu, MD, FACP, director of HIV Clinical Trials program at Yale School of Medicine. “We are especially pleased to see that Descovy, unlike Truvada, did not result in a decrease in bone mineral density among younger participants and that more favorable measures of renal function were observed among study participants including older individuals and those with moderate renal impairment.”

References:

1. Gilead Presents 96-Week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy for HIV PrEP in At-Risk Populations [news release]. Gilead’s website. https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-presents-96-week-discover-trial-data-demonstrating-favorable-renal-and-bone-safety-profile-of-descovy-for-hiv-prep-in-at-risk-populations. Accessed March 10, 2020.